LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS

被引：0

作者：

Mueller, M. ^{[1
]}

Baccarani, M. ^{[2
]}

Deininger, M. W. ^{[3
]}

Guilhot, F. ^{[4
]}

Hochhaus, A. ^{[5
]}

Hughes, T. P. ^{[6
,7
]}

Shah, N. P. ^{[8
]}

Talpaz, M. ^{[9
]}

Lustgarten, S. ^{[10
]}

Rivera, V. M. ^{[10
]}

Clackson, T. ^{[10
]}

Haluska, F. G. ^{[10
]}

Cortes, J. E. ^{[11
]}

机构：

[1] Univ Med Mannheim, Mannheim, Germany

[2] S Orsola Malpighi Univ Hosp, Bologna, Italy

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[4] CHU Poitiers, Inserm CIC 1402, Poitiers, France

[5] Jena Univ Hosp, Jena, Germany

[6] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[7] Univ Adelaide, Adelaide, SA, Australia

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[10] ARIAD Pharmaceut Inc, Cambridge, MA USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P615

引用

页码：239 / 239

页数：1

共 43 条